 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...910111213141516171819...2425» |
- | Leukine (sargramostim) / Partner Therap
Enrollment change: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Oct 24, 2017
P2, N=25, Recruiting, Sponsor: University of Florida
N=15 --> 25
- | Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 16, 2017
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=15 --> 25 Trial primary completion date: Jan 2011 --> Aug 2003
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Phase classification, Metastases: Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Oct 12, 2017
P1, N=7, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Jan 2011 --> Aug 2003 Phase classification: P=N/A --> P1
- | Leukine (sargramostim) / Partner Therap
Enrollment open, Trial primary completion date: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Oct 12, 2017
P1, N=10, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Phase classification: P=N/A --> P1 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2017 --> Mar 2018
- | Leukine (sargramostim) / Partner Therap
New P2 trial: GPAD-3: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (clinicaltrials.gov) - Oct 8, 2017
P2, N=176, Not yet recruiting, Sponsor: Emory University
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Oct 7, 2017
P2, N=27, Recruiting, Sponsor: Robin Kate Kelley
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2017 --> Mar 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Oct 4, 2017
P2, N=340, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Sep 28, 2017
P2, N=44, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Apr 2007
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Enrollment change: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 18, 2017
P1, N=398, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Apr 2007 Recruiting --> Active, not recruiting | N=560 --> 398
- | Leukine (sargramostim) / Partner Therap
Trial initiation date: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Sep 14, 2017
P2, N=80, Active, not recruiting, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Active, not recruiting | N=560 --> 398 Initiation date: May 2016 --> Sep 2016
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1/2 trial, Metastases: REO13 Melanoma With of Without GM-CSF (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=16, Not yet recruiting, Sponsor: University of Leeds
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Trial initiation date: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Sep 12, 2017
P3, N=774, Not yet recruiting, Sponsor: Children's Oncology Group
Initiation date: May 2016 --> Sep 2016 Initiation date: Aug 2017 --> Dec 2017
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Aug 29, 2017
P=N/A, N=45, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Aug 2017 --> Dec 2017 Trial primary completion date: May 2017 --> May 2018
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Aug 29, 2017
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: May 2017 --> May 2018
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Jul 27, 2017
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2017 --> May 2018 Suspended --> Recruiting
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - Jul 26, 2017
P4, N=200, Recruiting, Sponsor: Mark Hall
Suspended --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Leukine (sargramostim) / Partner Therap
Enrollment closed, Enrollment change, Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Jul 17, 2017
P2, N=36, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting | N=56 --> 36 | Trial primary completion date: Dec 2017 --> Jul 2020
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Phase classification: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Jul 15, 2017
P, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | N=56 --> 36 | Trial primary completion date: Dec 2017 --> Jul 2020 Phase classification: P1/2 --> P
- | Leukine (sargramostim) / Partner Therap
Trial withdrawal, Metastases: Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 13, 2017
P2, N=0, Withdrawn, Sponsor: James Ahlgren
Phase classification: P1/2 --> P Completed --> Withdrawn
- | Leukine (sargramostim) / Partner Therap
Enrollment change: Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (clinicaltrials.gov) - Jul 12, 2017
P2, N=50, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Completed --> Withdrawn N=70 --> 50
- | Leukine (sargramostim) / Partner Therap
Trial completion: Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (clinicaltrials.gov) - Jul 11, 2017
P2, N=50, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=70 --> 50 Active, not recruiting --> Completed
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 6, 2017
P2, N=12, Completed, Sponsor: UbiVac
Active, not recruiting --> Completed Recruiting --> Completed | N=48 --> 12 | Trial primary completion date: Jul 2016 --> Nov 2016
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial suspension, PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Jun 28, 2017
P2/3, N=400, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=48 --> 12 | Trial primary completion date: Jul 2016 --> Nov 2016 Recruiting --> Suspended
- | Leukine (sargramostim) / Partner Therap
Trial initiation date: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Jun 21, 2017
P1, N=10, Not yet recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Suspended Initiation date: Jan 2017 --> Jul 2017
- | Campath (alemtuzumab) / Sanofi, Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion: Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jun 16, 2017
P2, N=33, Completed, Sponsor: Mayo Clinic
Initiation date: Jan 2017 --> Jul 2017 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
New P1/2 trial: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Jun 16, 2017
P1/2, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - Jun 12, 2017
P2, N=53, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial initiation date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jun 12, 2017
P1, N=19, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Initiation date: Jun 2014 --> Oct 2015
- | Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Enrollment change, Trial primary completion date: Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 9, 2017
P2, N=17, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Initiation date: Jun 2014 --> Oct 2015 N=26 --> 17 | Trial primary completion date: Dec 2018 --> Feb 2013
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Enrollment open: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Jun 8, 2017
P1/2, N=40, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=26 --> 17 | Trial primary completion date: Dec 2018 --> Feb 2013 Suspended --> Recruiting
- | AST-302 / Aston Sci., EpiThany
Trial primary completion date, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Jun 8, 2017
P1, N=30, Recruiting, Sponsor: University of Washington
Suspended --> Recruiting Trial primary completion date: Dec 2019 --> Sep 2024
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - May 30, 2017
P2, N=71, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2019 --> Sep 2024 Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - May 25, 2017
P=N/A, N=23, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 Trial primary completion date: Sep 2015 --> May 2017
- | Leukine (sargramostim) / Partner Therap
Enrollment closed: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - May 24, 2017
P2, N=40, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Sep 2015 --> May 2017 Recruiting --> Active, not recruiting
- | ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial primary completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - May 19, 2017
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2017 --> Apr 2017
- | Clinical: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - May 17, 2017
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Oct 2017 --> Apr 2017 Trial primary completion date: May 2017 --> May 2018
- | Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Trial completion, Trial initiation date, Trial primary completion date, Metastases: Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim (clinicaltrials.gov) - May 17, 2017
P=N/A, N=270, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: May 2017 --> May 2018 Not yet recruiting --> Completed | Initiation date: Sep 2012 --> Apr 2013 | Trial primary completion date: Sep 2013 --> May 2013
- | Leukine (sargramostim) / Partner Therap
Biomarker, Trial completion, Metastases: Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim (clinicaltrials.gov) - May 17, 2017
P=N/A, N=48, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed | Initiation date: Sep 2012 --> Apr 2013 | Trial primary completion date: Sep 2013 --> May 2013 Not yet recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
New P1 trial, IO biomarker, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - May 16, 2017
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - May 4, 2017
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Trial primary completion date: Apr 2017 --> Apr 2018
- |||| Leukine (sargramostim) / Partner Therap
Trial primary completion date, Biopsy: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma (clinicaltrials.gov) - Apr 26, 2017
P3, N=380, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
New P3 trial: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Apr 25, 2017
P3, N=774, Not yet recruiting, Sponsor: Children's Oncology Group
- | Leukine (sargramostim) / Partner Therap, FR Alpha Peptide Vaccine / National Cancer Institute
P2 data: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - Apr 14, 2017
P2, N=280, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Enrollment status, Combination therapy: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (clinicaltrials.gov) - Apr 13, 2017
P2, N=75, Enrolling by invitation, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation
- | Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2017
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Recruiting --> Enrolling by invitation Trial primary completion date: Jan 2017 --> Jan 2018
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Apr 7, 2017
P2, N=300, Recruiting, Sponsor: George E. Peoples
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2017 --> Jun 2019
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=50, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2017 --> Jun 2019 Trial primary completion date: Apr 2017 --> Apr 2018
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal, Trial primary completion date: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Apr 7, 2017
P2, N=0, Withdrawn, Sponsor: Sanofi
Trial primary completion date: Apr 2017 --> Apr 2018 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Mar 2017
- |||| biropepimut-S (GL-0817) / Gliknik
Enrollment open: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Apr 7, 2017
P2, N=80, Recruiting, Sponsor: Gliknik Inc.
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Mar 2017 Not yet recruiting --> Recruiting
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (clinicaltrials.gov) - Apr 6, 2017
P2, N=100, Recruiting, Sponsor: Cancer Insight, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2018 --> Dec 2019